Literature DB >> 27531060

Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension.

Vanessa de Almeida Belo1, Juliana Montenegro Parente1, José Eduardo Tanus-Santos1, Michele M Castro2.   

Abstract

Increased matrix metalloproteinase (MMP)-2 is implicated in the vascular remodeling of hypertension. Calponin-1 is a contractile protein, and its absence is associated with vascular smooth muscle cell (VSMC) phenotype switch, which leads to migration and remodeling. We evaluated whether increased MMP-2 activity precedes chronic vascular remodeling by decreasing calponin-1 and inducing VSMC proliferation. Sham or two kidney-one clip (2K1C) rats were treated with doxycycline at 30mg/kg/day. Systolic blood pressure was increased in the 2K1C rats after 1 and 2weeks post-surgery, and doxycycline was effective to reduce it only at 2weeks of hypertension (p<0.05). Increased activity of MMP-2 was observed in aortas from 2K1C at 1 and 2weeks of hypertension, followed by increased VSMC proliferation, and those effects were abolished by treating 2K1C rats with doxycycline (p<0.05). Increased aortic media to lumen ratio started to emerge in 2K1C rats at 1week of hypertension, and it was established by 2weeks. MMP-2 and calponin-1 co-localized in the cytosol of VSMC. Aortas from 2K1C rats showed a significant reduction in calponin-1 levels at 1week of hypertension, and doxycycline prevented its loss (p<0.05). However, at 2weeks of hypertension, calponin-1 was upregulated in 2K1C (p<0.05 vs. Sham groups). The mRNA levels of calponin-1 were not altered in the aortas of 2K1C at 1week of hypertension. MMP-2 may contribute to the post-translational decrease in calponin-1, thus culminating in hypertension-induced maladaptive arterial remodeling.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arterial hypertension; Calponin-1; Matrix metalloproteinase-2; Vascular remodeling

Mesh:

Substances:

Year:  2016        PMID: 27531060     DOI: 10.1016/j.bcp.2016.08.012

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 2.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

3.  Notch2 and Proteomic Signatures in Mouse Neointimal Lesion Formation.

Authors:  Sarah M Peterson; Jacqueline E Turner; Anne Harrington; Jessica Davis-Knowlton; Volkhard Lindner; Thomas Gridley; Calvin P H Vary; Lucy Liaw
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-31       Impact factor: 8.311

Review 4.  Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations.

Authors:  Alejandro F Prado; Rose I M Batista; Jose E Tanus-Santos; Raquel F Gerlach
Journal:  Biomolecules       Date:  2021-04-16

5.  Correlation Between Matrix Metalloproteinases With Coronary Artery Lesion Caused by Kawasaki Disease.

Authors:  Fang Tian; Linxi Ma; Renbing Zhao; Lijuan Ji; Xiufen Wang; Wenli Sun; Yu Jiang
Journal:  Front Pediatr       Date:  2022-02-11       Impact factor: 3.418

6.  Age- and Phenotype-Dependent Changes in Circulating MMP-2 and MMP-9 Activities in Normotensive and Hypertensive Rats.

Authors:  Marta Kollarova; Angelika Puzserova; Peter Balis; Dominika Radosinska; Lubomira Tothova; Monika Bartekova; Miroslav Barancik; Jana Radosinska
Journal:  Int J Mol Sci       Date:  2020-10-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.